Citius Oncology, Inc. (CTOR)

Citius Oncology Statistics

Total Valuation

Citius Oncology has a market cap or net worth of $101.89 million. The enterprise value is $107.35 million.

Market Cap	101.89M
Enterprise Value	107.35M

Important Dates

The next estimated earnings date is Friday, December 26, 2025, after market close.

Earnings Date	Dec 26, 2025
Ex-Dividend Date	n/a

Share Statistics

Citius Oncology has 83.51 million shares outstanding. The number of shares has increased by 5.32% in one year.

Current Share Class	83.51M
Shares Outstanding	83.51M
Shares Change (YoY)	+5.32%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	7.33%
Owned by Institutions (%)	0.80%
Float	11.34M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	2.76
P/TBV Ratio	3.20
P/FCF Ratio	n/a
P/OCF Ratio	819.52
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.35, with a Debt / Equity ratio of 0.12.

Current Ratio	0.35
Quick Ratio	n/a
Debt / Equity	0.12
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-158.50

Financial Efficiency

Return on equity (ROE) is -107.54% and return on invested capital (ROIC) is -59.84%.

Return on Equity (ROE)	-107.54%
Return on Assets (ROA)	-22.47%
Return on Invested Capital (ROIC)	-59.84%
Return on Capital Employed (ROCE)	-65.81%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Citius Oncology has paid $936,720 in taxes.

Income Tax	936,720
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +15.09% in the last 52 weeks. The beta is 2.91, so Citius Oncology's price volatility has been higher than the market average.

Beta (5Y)	2.91
52-Week Price Change	+15.09%
50-Day Moving Average	1.72
200-Day Moving Average	1.53
Relative Strength Index (RSI)	21.80
Average Volume (20 Days)	166,853

Short Selling Information

The latest short interest is 251,359, so 0.30% of the outstanding shares have been sold short.

Short Interest	251,359
Short Previous Month	150,902
Short % of Shares Out	0.30%
Short % of Float	2.22%
Short Ratio (days to cover)	0.97

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-25.48M
Pretax Income	-25.64M
Net Income	-26.58M
EBITDA	n/a
EBIT	-25.48M
Earnings Per Share (EPS)	-$0.37

Balance Sheet

The company has $112 in cash and $3.80 million in debt, giving a net cash position of -$3.80 million or -$0.05 per share.

Cash & Cash Equivalents	112
Total Debt	3.80M
Net Cash	-3.80M
Net Cash Per Share	-$0.05
Equity (Book Value)	32.40M
Book Value Per Share	0.45
Working Capital	-34.68M

Cash Flow

Operating Cash Flow	126,353
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Citius Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-5.32%
Shareholder Yield	-5.32%
Earnings Yield	-25.67%
FCF Yield	n/a

Analyst Forecast

The average price target for Citius Oncology is $6.00, which is 391.80% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$6.00
Price Target Difference	391.80%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	3